Date: Mon 20/05/2019 - Sat 31/10/2020
Provider: Luxottica Institute of Learning
Optometrist Credits: 1 Clinical Diagnostic Credit + 1 Glaucoma Event Credit
Event Type(s): Online
Number: 09 929 3274
Glaucoma research drives on. Developing and evaluating new MIGS devices, novel means of drug delivery, the cellular mechanisms of ganglion cell death, and the role of co-morbid ocular disease are fruitful avenues of current research.
Glaucoma is the leading cause of irreversible vision loss globally and in Australia.1 Lowering the intraocular pressure (IOP) has been shown in randomised controlled trials to reduce the incidence and progression of glaucomatous field loss,2 and at present this remains the only proven strategy for managing glaucoma.
The ideal IOP lowering treatment should be effective, simple to administer, symptom free, low risk, with a high success rate, and long duration of action. Glaucoma management still awaits this panacea. However our developing understanding of aqueous outflow and the mechanisms of trabecular dysfunction are leading to improved therapeutic options for patients with glaucoma.
Eye drops have been the central pillar of IOP lowering treatment, with drainage surgery a successful option when the risk of vision loss outweighs the risk of surgical complications. The critical limitations of eye drops are adherence and intolerance which cause a significant burden on our patients.3 Novel drug targets and delivery options, laser trabeculoplasty, and new surgical devices including Minimally Invasive Glaucoma Surgery (MIGS) have shifted the management spectrum available to patients suffering from glaucoma, and from the side effects of its treatment.